Airship Receives Highest Product Scores Across All Three Use Cases in Gartner’s Critical Capabilities for Mobile Marketing Platforms
Customer engagement company Airship today announced that it received the highest Product Scores across all three Use Cases in Gartner’s 2019 Critical Capabilities for Mobile Marketing Platforms,1 including the Acquisition, Engagement and Retention Use Cases. A complimentary copy of the report is available here.
“Airship is setting new standards in real-time customer experience — the critical element of brand success today — and believe our scores in Gartner’s Critical Capabilities report reflect the industry-leading results our customers and partners are seeing around the world,” said Brett Caine, CEO and president, Airship. “Airship has enabled many of the world’s leading global brands to deploy innovative customer engagement strategies for more than a decade, and have proven time and time again that we are unmatched in keeping our clients at the forefront of emerging consumer trends and digital channels so they can stay ahead of their competition.”
According to Gartner, “As demand for strong mobile and multimodal engagement capabilities grows to keep pace with consumer expectations, so will the complexity for mobile marketers. This means choosing an MMP is more important than the average vendor selection: it’s a critical strategic decision for the entire marketing team.”
Gartner evaluated 18 mobile marketing platform vendors as part of the Critical Capabilities report, a companion report to the Gartner Magic Quadrant, offering a comparative analysis that scores competing products or services against a set of critical differentiators identified by Gartner. In Gartner’s 2019 Magic Quadrant for Mobile Marketing Platforms 2 Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in the Leaders quadrant overall (read the details or get the report).
The Critical Capabilities report states, "As younger generations continue to lead the way in mobile adoption and use,3 brands are tuning their marketing investments toward mobile accordingly. Gartner’s “CMO Spend Survey 2018-2019: Marketers Proceed Into Uncharted Waters With Confidence” found that a full 77% of CMOs surveyed reported plans to increase their mobile marketing budgets through 2020, ranking highest among 15 marketing capabilities measured.”
Today Airship also launched its first integration with Apptimize, the most adopted solution for testing and innovating user experiences across mobile apps and other digital channels, which it recently acquired to unify digital engagement and digital experimentation. With Coordinated Experimentation, marketers and developers can now easily synchronize Airship messaging and Apptimize tests to nurture experiments and create consistent experiences across messaging channels and digital properties.
1 Gartner “Critical Capabilities for Mobile Marketing Platforms” by Charles S. Golvin, Mike McGuire, October 21, 2019
2 Gartner “Magic Quadrant for Mobile Marketing Platforms” by Mike McGuire, Charles Golvin, July 15, 2019
Gartner Disclosure
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, coordinated messages across channels.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform, read our blog or follow us on Twitter, LinkedIn, Facebook and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191025005060/en/
Contact information
Media Contacts:
North America:
Danielle Stickler
Bateman Group
+1 415-749-9124
airship@bateman-group.com
Corey Gault
Airship
+1 503-206-9164
corey@airship.com
EMEA:
Nina Meyer
Airship
+33 1 44 56 87 10
nina.meyer@airship.com
UK:
Lucinda Layton
Hotwire UK
+44 20 7608 2500
Airship@hotwireglobal.com
France:
Marion Fajgenbaum / Marine Cressot
Hotwire France
+33 14 312 55 68 / 69
AirshipFR@hotwireglobal.com
Germany:
Julia da Silva Bastos
Hotwire Germany
+49 89 2620 81 89
airshipde@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom